ProofPilot Announces Series C Funding
ProofPilot Announces Series C Funding
NEW YORK, July 11, 2024 /PRNewswire/ -- ProofPilot, a leading Clinical Experience Platform (CXP), announced the closing of its Series C financing, led by Sopris Capital with Mitsui & Co. (U.S.A.), Inc. participating.
美國紐約，2024年7月11日 /美通社/ -- ProofPilot, 一家著名的臨床體驗平台（CXP）宣佈完成了C輪融資，由Sopris Capital領投，Mitsui & Co. (美國) Inc. 參投。
"Much of the focus in clinical trial technology has been on data capture and AI, but supporting the clinical trial experience for stakeholders has taken a backseat," said Chris Venezia, CEO of ProofPilot. "Our strategic advisory board, comprising patients, research sites, and sponsors, is solving the right challenges and needs to modernize experiences for all stakeholders. This repeat investment from our Series B investors recognizes the market's need and provides us with resources to scale and accelerate life-saving therapies."
ProofPilot的CEO Chris Venezia表示："在臨床試驗技術領域，大部分的關注都集中在數據採集和人工智能上，而爲相關利益相關者提供支持則被忽視了。我們的戰略顧問委員會由病患、研究機構和贊助商組成，正在解決正確的挑戰和需求，以實現對所有利益相關者體驗的現代化。我們的B輪投資者再次投資反映了市場需求，併爲我們提供了規模化和加速拯救生命療法的資源。"
ProofPilot's platform, StudyCoPilot, centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. The products and services support key initiatives like improving DE&I, streamlining recruitment & retention, and easing site burden. ProofPilot has scaled its capabilities for enterprise use and has industry leading pharmaceutical clients deploying StudyCoPilot globally.
ProofPilot的平台StudyCoPilot集中和簡化贊助商、病患和研究機構在臨床試驗體驗期間的溝通。該產品與服務支持改善多元文化、簡化招募與留存以及減輕研究機構的負擔等關鍵計劃。ProofPilot已將其能力應用於企業用戶，並擁有全球領先的藥品客戶在全球部署StudyCoPilot。
"The sky is the limit with ProofPilot, and we are excited about investing in the company. We have tremendous confidence in the team and are proud to see some of the world's leading life sciences companies adopt the technology," said Abinav Sankar, Partner at Sopris Capital.
Sopris Capital合夥人Abinav Sankar表示："ProofPilot的發展前景無限，我們很高興投資此公司。我們對團隊有極大信心，並很自豪地看到世界領先的生命科學公司採用此技術。"
About ProofPilot
關於ProofPilot
ProofPilot enhances clinical trials with its Clinical Experience Platform (CXP). The StudyCoPilot platform centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. Learn more at: .
ProofPilot通過其臨床體驗平台（CXP）增強臨床試驗。StudyCoPilot平台集中和簡化贊助商、病患和研究機構在臨床試驗體驗期間的溝通。了解更多：。
About Sopris Capital
關於Sopris Capital
Sopris Capital invests growth equity in technology-enabled business services and SaaS companies solving critical pain points. Sopris partners with fast-growing companies with a validated business model, proven product/market fit, and a strong management team. Learn more at: .
Sopris Capital在爲解決關鍵痛點的技術業務服務和SaaS公司中進行增長股權投資。Sopris與具有驗證的商業模式、證明的產品/市場適配度和強大的管理團隊的快速增長公司合作。了解更多：。
About Mitsui
關於三井
Mitsui & Co. (U.S.A.), Inc. ("Mitsui USA"), a subsidiary of Mitsui & Co., Ltd., Tokyo, Japan, is one of the most diversified trading, investment, and service enterprises globally. Mitsui & Co. pursues "360° business innovation" across product sales, logistics, financing, and major international infrastructure projects. More information on Mitsui USA can be found at .
三井洲(美國)有限公司(Mitsui & Co. (U.S.A.), Inc.)是日本三井株式會社(Mitsui & Co., Ltd., Tokyo, Japan)旗下的子公司之一，是全球最多元化的貿易、投資和服務企業之一。三井株式會社在產品銷售、物流、融資和大型國際基礎設施項目方面追求"360°商業創新"。有關Mitsui USA的更多信息，請訪問 。
Media Contacts: Colleen Yang, [email protected]
媒體聯繫人：Colleen Yang, [email protected]
SOURCE ProofPilot
來源：ProofPilot
譯文內容由第三人軟體翻譯。